
Opinion|Videos|July 19, 2024
EHA 2024: Teclistimab in High-Risk Relapsed/Refractory Multiple Myeloma
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses the safety and usefulness of tesclistimab in patients with high-risk refractory multiple myeloma.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Discuss the data presented at EHA 2024 on the efficacy and safety of teclistimab in patients with relapsed/refractory multiple myeloma (RRMM) with high-risk features: a subgroup analysis of the phase 1/2 MajesTEC-1 study. (Abstract)
- What was the objective of the subgroup analysis of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- N=165
- N=24 aged ≥75 years
- N=20 ISS stage III
- N=38 high-risk cytogenetics
- N=28 extramedullary disease
- N=18 bone marrow plasma cells
- N=50 penta-drug refractory
- Median follow up ~30 months across subgroups
- Objective Response Rate (ORR)
- Median duration of response (mDOR)
- Safety
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Belantamab Mafodotin Combo for Relapsed or Refractory Multiple Myeloma
2
Guidelines for Bronchiectasis Highlight Multiple Treatment Methods
3
IEHP CEO Weighs in: Who Pays the Price When Millions Lose Medicaid Coverage?
4
Many US Health Care Workers Face Poverty, Food Insecurity, and Housing Instability
5
















































